Sotera Health Continues Capacity Expansion Efforts

Capuski/iStock via Getty Images

A Quick Take On Sotera Health

Sotera Health Company (NASDAQ:SHC) went nationalist connected November 19, 2020, raising astir $1.1 cardinal successful gross proceeds successful an IPO that was priced astatine $23.00 per share.

The company provides sterilization and laboratory testing services to aesculapian instrumentality and pharmaceutical companies.

While SHC banal rebounded successful January pinch nan colony of Illinois claims, location are still important uncertainties pinch respect to nan institution and its ineligible liabilities.

Until those uncertainties are resolved, I’m connected Hold for SHC.

Sotera Health Overview

Broadview Heights, Ohio-based Sotera was founded to supply end-to-end sterilization, microbiological and analytical testing services.

Management is headed by Chairman and CEO Michael Petras, Jr., who has been pinch nan patient since 2016 and was antecedently CEO of Post-Acute Solutions astatine Cardinal Health.

In addition, nan patient provides advisory services for pharmaceutical and nutrient processors worldwide.

The institution counts "more than 40 of nan apical 50 aesculapian instrumentality companies and 8 of nan apical 10 world pharmaceutical companies (based connected revenue)" arsenic customers.

It has a full of much than 5,800 customers successful complete 50 countries.

Sotera’s Market & Competition

According to a 2020 marketplace research report, nan world marketplace for sterilization services was an estimated $2.7 cardinal successful 2019 and is forecast to scope $4.4 cardinal by 2027.

This represents a forecast CAGR of 6.3% from 2020 to 2027.

The main drivers for this expected maturation are a continued emergence successful nan number of aged group on pinch chronic illnesses and improvement opportunities successful emerging countries.

Also, further maturation is expected to travel from nan aesculapian instrumentality industry, which is seeing stringent regulatory requirements driving sterilization work demand.

Major competitory aliases different manufacture participants include:

• Applied Sterilization Technologies (STERIS) (STE)

• Regional/smaller outsourced sterilization work firms

Sotera’s Recent Financial Performance

• Total gross by 4th has risen according to nan pursuing chart:

Total Revenue (Seeking Alpha)

• Gross profit separator by 4th has produced nan pursuing trajectory:

Gross Profit Margin (Seeking Alpha)

• Selling, G&A expenses arsenic a percent of full gross by 4th person fluctuated per nan floor plan below:

Selling, G&A % Of Revenue (Seeking Alpha)

• Operating income by 4th has trended unevenly higher successful caller quarters:

Operating Income (Seeking Alpha)

• Earnings per stock (Diluted) person remained affirmative successful nan past 7 quarters:

Earnings Per Share (Seeking Alpha)

(All information successful nan supra charts is GAAP.)

In nan past 12 months, SHC’s banal value has dropped 22.4% vs. that of Steris’ autumn of 21.6%, arsenic nan floor plan indicates below:

52-Week Stock Price Comparison (Seeking Alpha)

Valuation And Other Metrics For Sotera Health

Below is simply a array of applicable capitalization and valuation figures for nan company:

(Source - Seeking Alpha.)

As a reference, a applicable partial nationalist comparable would beryllium STERIS plc; shown beneath is simply a comparison of their superior valuation metrics:

(Source - Seeking Alpha.)

Commentary On Sotera Health

In its past net telephone (Source - Seeking Alpha), covering Q3 2022’s results, guidance highlighted nan antagonistic macroeconomic situation nan patient is experiencing, albeit pinch immoderate areas of improvement.

Its Sterigenics conception saw "solid demand" arsenic it sought to "offset ostentation pressures being felt astir nan globe."

The conception besides made advancement connected its capacity description and installation enhancement initiatives.

As to its financial results, full gross grew 10% year-over-year, while adjusted EBITDA roseate 7.3%.

Adjusted EBITDA usually excludes stock-based compensation and one-time items.

Operating income has trended somewhat higher recently, while net per stock person trended little successful nan past fewer quarters.

For nan balance sheet, nan patient vanished nan 4th pinch $164.7 cardinal successful cash, equivalents, and short-term investments and $1.75 cardinal successful semipermanent debt.

Over nan trailing 12 months, free rate travel was $90.5 million, of which superior expenditures accounted for $151.9 million. The institution paid $18.3 cardinal successful stock-based compensation successful nan past 4 quarters.

Looking ahead, guidance expects afloat twelvemonth 2022 gross maturation to beryllium astir 7.5% astatine nan midpoint of nan range, and adjusted EBITDA to turn by 5% astatine nan midpoint.

Regarding valuation, nan marketplace is valuing SHC astatine an Enterprise Value / EBITDA aggregate of 17.8x, somewhat higher than competitor STERIS’ 16.3x multiple, apt owed to SHC’s affirmative nett income margin.

The superior risks to Sotera Health Company’s outlook are continued slow macroeconomic dynamics for definite of its segments arsenic good arsenic further ineligible claims against nan firm, specified arsenic people actions by shareholders who impeach guidance of misleading investors related to its merchandise liability characteristics from nan usage of Ethylene Oxide.

While Sotera Health Company banal rebounded successful January pinch nan colony of Illinois claims, location are still important uncertainties pinch respect to nan institution and its ineligible liabilities.

Until those uncertainties are resolved, I’m connected Hold for Sotera Health Company.

Gain Insight and actionable accusation connected U.S. IPOs pinch IPO Edge research.

Members of IPO Edge get nan latest IPO research, news, and manufacture analysis.

Get started pinch a free trial!